HC Wainwright Comments on CG Oncology FY2029 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for CG Oncology in a research report issued to clients and investors on Monday, March 31st. HC Wainwright analyst A. Maldonado forecasts that the company will earn $1.34 per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.11 million.

Several other research firms also recently issued reports on CGON. Royal Bank of Canada reissued an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research report on Friday, December 6th. TD Cowen assumed coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Finally, Morgan Stanley reissued an “overweight” rating and set a $55.00 target price on shares of CG Oncology in a research report on Friday, March 7th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $63.88.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $22.05 on Wednesday. The stock has a market capitalization of $1.68 billion, a PE ratio of -15.53 and a beta of 1.60. CG Oncology has a 52 week low of $21.93 and a 52 week high of $46.99. The stock has a 50 day moving average price of $27.66 and a two-hundred day moving average price of $31.63.

Institutional Trading of CG Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in CG Oncology in the 4th quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CG Oncology in the 4th quarter worth about $68,000. KLP Kapitalforvaltning AS purchased a new position in shares of CG Oncology in the 4th quarter worth about $100,000. Federated Hermes Inc. bought a new position in CG Oncology during the fourth quarter valued at about $172,000. Finally, Meeder Asset Management Inc. purchased a new stake in CG Oncology during the fourth quarter worth about $189,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.